WASHINGTON DC (May 24, 2019) — Today, the US Food and Drug Administration (FDA) permitted marketing of the Synovasure Lateral Flow Test Kit as an aid for the detection of periprosthetic joint-infection (infection around a joint replacement) in the synovial (lubricant) fluid of patients being evaluated for revision surgery, which is surgery performed to replace or compensate for a failed implant.

“Prior to today’s authorization, there were no FDA-authorized diagnostic tests specifically designed to help health care professionals determine whether the inflammation around a prosthetic joint was due to an infection or another cause,” said Tim Stenzel MD/PhD, director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health. “With this test, health-care professionals now have an additional option available to aid their clinical assessment as to whether the patient has an infection and requires revision surgery. Whereas before surgeons may have opted for surgery when the presence of an infection was unclear, with this test, they have more information and could potentially reduce patient risk by avoiding unnecessary revision operations for replacement joints.”

Joint replacement is a surgical treatment option for people with severe joint-damage, including the knees or hips. During a joint replacement-surgery, the surgeon removes damaged cartilage and bone from the surface of the joint and replaces it with a prosthetic joint-implant. Potential complications of joint replacement include scarring, inflammation, blood clots, and infections. If an infection occurs, it can lead to pain, redness, swelling, and decreased joint-function, and potentially require antibiotics and revision surgery to treat the infection and install a new prosthetic implant. Physicians typically evaluate for potential infections using X-ray images or laboratory analysis of joint fluid, which can take days for results.

The Synovasure Lateral Flow Test Kit detects proteins called human alpha defensins in the synovial fluid of patients with a total joint-replacement in approximately 10 minutes. Alpha defensins are antimicrobial proteins released by activated neutrophils (white blood-cells) in response to infection. The Synovasure Lateral Flow Test Kit is intended as an aid to determine whether there is an infection present in synovial fluid. It is not intended to identify a specific type of infection. The test results are also intended to be used in conjunction with other clinical and diagnostic findings to aid in a patient’s diagnosis of prosthetic joint-infection.

The FDA reviewed data from a clinical study that analyzed 305 prospective synovial fluid samples collected from individuals with a total knee or hip/joint replacement who were being evaluated for revision surgery. The study showed that 89.5% of subjects with an infection diagnosis based on standard-of-care criteria were also identified as positive for alpha defensin by the Synovasure Lateral Flow Test Kit.

The FDA reviewed data for the Synovasure Lateral Flow Test Kit through the de novo premarket review pathway, a regulatory pathway for low-to-moderate-risk devices of a new type. Along with this authorization, the FDA is establishing criteria, called special controls, which determine the requirements for demonstrating the safety and effectiveness of tests to detect and measure non-microbial analytes (substances) that aid in the detection and identification of localized human infections. These special controls, when met along with general controls, provide a reasonable assurance of safety and effectiveness for these tests.

The FDA granted marketing authorization of the Synovasure Lateral Flow Test Kit to CD Diagnostics Inc.

The FDA, an agency within the US Department of Health and Human Services, promotes and protects the public health by, among other things, assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines, and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food-supply, cosmetics, dietary-supplements, products that give off electronic radiation, and for regulating tobacco products.

Support the River Cities' Reader

Get 12 Reader issues mailed monthly for $48/year.

Old School Subscription for Your Support

Get the printed Reader edition mailed to you (or anyone you want) first-class for 12 months for $48.
$24 goes to postage and handling, $24 goes to keeping the doors open!

Click this link to Old School Subscribe now.



Help Keep the Reader Alive and Free Since '93!

 

"We're the River Cities' Reader, and we've kept the Quad Cities' only independently owned newspaper alive and free since 1993.

So please help the Reader keep going with your one-time, monthly, or annual support. With your financial support the Reader can continue providing uncensored, non-scripted, and independent journalism alongside the Quad Cities' area's most comprehensive cultural coverage." - Todd McGreevy, Publisher